SCHEMBL770829

SCHEMBL770829

NC(=O)c1ccccc1[CH]c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCAT2 O15382 1/20 0.52
ALDH1A1 P00352 6/20 0.51
HPGD P15428 5/20 0.51
MAPT P10636 4/20 0.51
KDM4E B2RXH2 4/20 0.51
LMNA P02545 2/20 0.51
TSHR P16473 2/20 0.47
HSD17B10 Q99714 2/20 0.47
SIRT2 Q8IXJ6 1/20 0.46
METAP2 P50579 1/20 0.44
SIRT1 Q96EB6 2/20 0.43
CTNNB1 P35222 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
HTT P42858 1/20 0.42
PARP1 P09874 2/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
POLB P06746 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8579469 0.87 ALDH1A1 (0.54) BCAT2ALDH1A1HPGDMAPTKDM4E
SCHEMBL3730248 0.85 KDM4E (0.51) BCAT2ALDH1A1HPGDMAPTKDM4E
SCHEMBL6156425 0.83 ALDH1A1 (0.54) ALDH1A1HPGDMAPTKDM4ELMNA
SCHEMBL31678976 0.82 SIRT2 (0.57) BCAT2ALDH1A1HPGDMAPTKDM4E
SCHEMBL3639133 0.82 SIRT2 (0.57) BCAT2ALDH1A1HPGDMAPTKDM4E
SCHEMBL2037764 0.82 SIRT2 (0.57) BCAT2ALDH1A1HPGDMAPTKDM4E
SCHEMBL7592270 0.80 F2 (0.41) BCAT2ALDH1A1HPGDMAPTKDM4E
SCHEMBL4976470 0.80 ALDH1A1 (0.36) BCAT2ALDH1A1HPGDMAPTKDM4E
Styrene SCHEMBL4566718 0.79 ALDH1A1 (0.50) BCAT2ALDH1A1HPGDMAPTKDM4E
SCHEMBL3402378 0.79 NFE2L2 (0.48) ALDH1A1HPGDMAPTKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110124051-B Macromolecules 星法马私人有限公司 2022-10-21 CN claimed
EP-2729179-B1 MACROMOLECULES STARPHARMA PTY LTD (AU) 2020-09-23 EP claimed
CN-110124051-A Macromolecular 星法马私人有限公司 2019-08-16 CN claimed
EP-2091951-B1 PYRIDO[2,3-B]PYRAZINE AND [1,8]-NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS CEPHALON INC (US) 2018-02-28 EP claimed
EP-2661433-B1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) NOVARTIS AG (CH) 2017-08-16 EP claimed
EP-1940916-B1 MACROMOLECULAR COMPOUNDS HAVING CONTROLLED STOICHIOMETRY STARPHARMA PTY LTD (AU) 2016-12-14 EP claimed
EP-1888596-B1 SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF MEDICAMENTS GRUENENTHAL GMBH (DE) 2014-10-22 EP claimed
US-8258259-B2 Macromolecular compounds having controlled stoichiometry STARPHARMA PTY LIMITED (AU) 2012-09-04 US claimed
EP-1874748-B1 2 -AMINOCARBONYL SUBSTITUTED PIPERAZINE OR DIAZA-CYCLIC COMPOUNDS AS APOPTOSIS PROTEIN INHIBITOR (IAP) MODULATORS NOVARTIS AG (CH) 2009-08-12 EP claimed
EP-1869038-B1 SUBSTITUTED 5,6,7,8-TETRAHYDRO-IMIDAZO[1,2-A]PYRIDIN-2-YLAMINE COMPOUNDS AND THEIR USE FOR PRODUCING DRUGS GRUENENTHAL GMBH (DE) 2009-07-08 EP claimed
US-20090118467-A1 Macromolecular Compounds Having Controlled Stoichiometry STARPHARMA PTY LIMITED (AU) 2009-05-07 US claimed
EP-1633348-B1 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B sb 1 /sb RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES ELAN PHARM INC (US) 2008-10-08 EP claimed
EP-1940916-A1 MACROMOLECULAR COMPOUNDS HAVING CONTROLLED STOICHIOMETRY Starpharma Pty Limited (AU) 2008-07-09 EP claimed
WO-2007048190-A1 MACROMOLECULAR COMPOUNDS HAVING CONTROLLED STOICHIOMETRY STARPHARMA PTY LIMITED (AU) 2007-05-03 WO claimed
EP-1401841-B1 SUBSTITUTED 1-OXA-2,8-DIAZA-SPIRO 4,5]DEC-2-ENE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF PAIN GRUENENTHAL GMBH (DE) 2005-08-24 EP claimed
EP-1150946-B1 ARYLALKANOYL DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AVENTIS PHARMA GMBH (DE) 2005-03-30 EP claimed
US-20250361271-A1 PEPTIDE AGONIST THE UNIVERSITY OF BIRMINGHAM (GB) 2025-11-27 US disclosed
EP-4561604-A1 PEPTIDE AGONIST The University Of Birmingham (GB) 2025-06-04 EP disclosed
US-4086136-A Process for producing a peptide using a serine or thiol proteinase (ZAIDANHOJIN) SAGAMI CHEMICAL RESEARCH CENTER (JA) 1978-04-25 US disclosed
US-3954709-A Phenylethyl group containing resins for the synthesis of peptides THE REGENTS OF THE UNIVERSITY OF COLORADO (US) 1976-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250361271-A1 PEPTIDE AGONIST CCL2, ACKR3, PROKR1 BCAT2 2544/4885ALDH1A1 4730/4885HPGD 3968/4885
US-20090118467-A1 Macromolecular Compounds Having Controlled Stoichiometry MICA, PICALM, CLTB BCAT2 1960/4885ALDH1A1 4603/4885HPGD 3993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.